Successively partnering with Hengrui, Qilu and Shigao! How can Akso lead the new digitalization trend in pharmaceutical compliance?

Amid the wave of compliance-driven digital transformation in the pharmaceutical industry, Akso (Chongqing) Information Technology Co., Ltd. has emerged as a highly sought-after partner. Top pharmaceutical enterprises including Qilu Pharmaceutical, Hengrui Medicine, CSPC Pharmaceutical Group, and Kelun Pharmaceutical have extended olive branches to establish in-depth collaborations.

To date, Akso has successfully supported over 150 pharmaceutical companies in implementing integrated digital platforms and group-wide deployment solutions. It has achieved an unprecedented 100% project launch rate — an industry-leading milestone — while maintaining consistently high customer satisfaction.

In a crowded pharmaceutical digitalization landscape, why do leading pharmaceutical companies favor Akso exclusively? What competitive advantages enable it to lead the sector in compliance-focused digital intelligence and unlock new industry potential? The answer lies in its robust product strength, solid operational foundation, and precise understanding of industry demands.

As a benchmark in the digitalization of quality management, Akso's core competitiveness starts with its proprietary core technologies, which form a formidable technical barrier. Its self-developed Akso eGxP, is an exclusive zero-code unified solution with all applications in one foundation with shared data.  It deeply integrates six core systems covering GxP document management, quality management,  training management,archive management,quality review and electronic record enabling fully integrated interconnection across all modules and eliminating the long-standing industry problem of "data silos" in traditional standalone systems.

Notably, the solution requires no manual secondary data entry, avoiding human errors at the source and drastically improving cross-process and cross-departmental collaborative efficiency — a critical necessity for pharmaceutical enterprises pursuing high efficiency and compliance.

In product development, Akso has taken the "challenging yet correct" path. Unlike the commonly used Category 5 custom-developed software in the industry, Akso has invested several times more in R&D to create higher-standard Category 4 configurable software. The advantages are immediate: traditional custom software involves long deployment cycles and high regulatory compliance risks, whereas Akso's configurable solution supports flexible, "building-block" configuration to quickly meet personalized customer needs. It also features strong scalability, low learning costs, and out-of-box usability, helping pharmaceutical companies avoid detours in their compliance digital transformation.

What puts pharmaceutical companies further at ease is that Akso's products achieve global compliance adaptability.The fully aligning with authoritative regulations from the FDA, EU, WHO, NMPA, and other global and domestic authorities. It synchronizes global regulatory updates in real time, enabling companies to shift from passive compliance to proactive compliance governance.

Its intelligent data governance capabilities automatically standardize data to fully meet ALCOA+ requirements, turning fragmented compliance data into core digital assets.

Its technological advancement, GMP compliance, and user-friendliness have earned high recognition from top clients. A QA director at a leading pharmaceutical company openly stated that, among many similar systems worldwide, Akso delivers the most superior overall performance.

If robust products represent Akso's "hard power", its steady business philosophy and mature service system serve as the "ballast" for sustainable development. Akso's core leadership has more than 30 years of deep experience in the pharmaceutical industry, with an incisive understanding of industry trends, compliance standards, and precise market insights. This has supported the establishment of a mature operational system and a solid strategic foundation for long-term growth.

While many enterprises pursue short-term gains, Akso remains committed to long-termism, covering the full business chain and building a closed-loop service ecosystem: from customized solution design and efficient deployment to ongoing post-launch maintenance. Supported by a responsive local service mechanism, its professional team provides one-on-one dedicated support throughout the project lifecycle, fundamentally resolving the industry-wide issue of unfinished projects — the key to its 100% project launch record.

Its reliable professional services have earned long-term, deep customer trust and built a highly loyal client base. In turn, a stable core team and mature service model have become the pillars of Akso's healthy operations, sustaining steady growth amid fierce industry competition.

The pharmaceutical compliance digital intelligence sector is experiencing unprecedented development opportunities. With the implementation of pivotal policies such as the Digital and Intelligent Transformation Plan for the Pharmaceutical Industry (2025–2030), compliance digitalization has evolved from an "optional initiative" to a "mandatory requirement" for survival and growth. A comprehensive regulatory framework has opened up vast market space.

As compliance supervision enters a deeper stage, traditional fragmented compliance solutions no longer suffice, making unified platform solutions the inevitable industry choice.

Meanwhile, the digital divide within the industry further unlocks Akso's market potential. Apart from leading pharmaceutical enterprises, most small and medium-sized pharmaceutical companies have not yet adopted professional quality management systems, leaving massive market demand waiting to be tapped. With strong products, a mature service system, and profound industry expertise, Akso stands out as a top contender in this market competition.

Backed by policy support, grounded in market demand, and empowered by its dual strengths in products and services, Akso's development path is clear. Going forward, this benchmark enterprise deeply rooted in pharmaceutical compliance digital intelligence will continue to empower more pharmaceutical companies through all-in-one solutions, drive industry-wide compliance and digital upgrading, and lead the pharmaceutical industry toward a new journey of high-quality development.